Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2525 USD | +4.12% | +2.23% | -88.09% |
Mar. 28 | Transcript : ENDRA Life Sciences Inc., Q4 2023 Earnings Call, Mar 28, 2024 | |
Mar. 28 | ENDRA Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | 1M | Sales 2025 * | - | Capitalization | 2.79M |
---|---|---|---|---|---|
Net income 2024 * | -12M | Net income 2025 * | - | EV / Sales 2024 * | 2.79 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.18
x | P/E ratio 2025 * |
-
| Employees | 21 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.85% |
Latest transcript on ENDRA Life Sciences Inc.
1 day | +4.12% | ||
1 week | +2.23% | ||
Current month | -56.47% | ||
1 month | -74.06% | ||
3 months | -75.25% | ||
6 months | -73.97% | ||
Current year | -88.09% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 14-12-31 | |
Irina Pestrikova
DFI | Director of Finance/CFO | 38 | 21-06-17 |
Michael Thornton
CTO | Chief Tech/Sci/R&D Officer | 55 | 06-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 13-06-30 | |
Alexander Tokman
BRD | Director/Board Member | 62 | 07-12-31 |
Michael Harsh
BRD | Director/Board Member | 69 | 14-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.2525 | +4.12% | 11,104 |
24-04-25 | 0.2425 | -6.69% | 35,436 |
24-04-24 | 0.2599 | +2.16% | 42,059 |
24-04-23 | 0.2544 | +1.68% | 37,025 |
24-04-22 | 0.2502 | +1.30% | 18,144 |
Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-88.09% | 2.79M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- NDRA Stock